WallStreetZenWallStreetZen

NASDAQ: JAZZ
Jazz Pharmaceuticals PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for JAZZ

Based on 12 analysts offering 12 month price targets for Jazz Pharmaceuticals PLC

Min Forecast
$147.00+33.31%
Avg Forecast
$183.08+66.03%
Max Forecast
$230.00+108.58%

Should I buy or sell JAZZ stock?

Based on 12 analysts offering ratings for Jazz Pharmaceuticals PLC.

Strong Buy
Strong Buy
7 analysts 58.33%
Buy
4 analysts 33.33%
Hold
1 analysts 8.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although JAZZ's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates JAZZ as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their JAZZ stock forecasts and price targets.

JAZZ stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-11
lockedlocked$00.00+00.00%2025-05-07
lockedlocked$00.00+00.00%2025-05-07
lockedlocked$00.00+00.00%2025-05-07
lockedlocked$00.00+00.00%2025-05-07
HC Wainwright & Co.
Top 20%
81
BuyMaintains$217.00+96.79%2025-03-10
UBS
Bottom 23%
23
Strong BuyUpgrades$179.00+62.33%2025-03-07
Truist Securities
Top 22%
79
Strong BuyMaintains$230.00+108.58%2025-03-06Find out why
Barclays
Bottom 7%
7
Strong BuyMaintains$200.00+81.37%2025-02-27
Cantor Fitzgerald
Top 3%
98
HoldDowngrades$150.00+36.03%2025-02-26

1 of 2

Forecast return on equity

Is JAZZ forecast to generate an efficient return?

Company
N/A
Industry
167.46%
Market
89.88%

Forecast return on assets

Is JAZZ forecast to generate an efficient return on assets?

Company
N/A
Industry
44.42%

JAZZ earnings per share forecast

What is JAZZ's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$2.06-73.53%
Avg 2 year Forecast
$17.79+128.38%
Avg 3 year Forecast
$20.72+166.02%
JAZZ's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

JAZZ revenue forecast

What is JAZZ's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$4.2B+4.36%
Avg 2 year Forecast
$4.5B+10.72%
Avg 3 year Forecast
$4.8B+18.72%
JAZZ's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

JAZZ earnings growth forecast

How is JAZZ forecast to perform vs Biotechnology companies and vs the US market?

Company
48.52%
Industry
9.69%
Market
15.82%
JAZZ's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
JAZZ's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
JAZZ's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

JAZZ revenue growth forecast

How is JAZZ forecast to perform vs Biotechnology companies and vs the US market?

Company
5.8%
Industry
57.01%
Market
10.4%
JAZZ's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
JAZZ's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

JAZZ vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
JAZZ$110.27$183.08+66.03%Strong Buy
IONS$41.73$54.67+31.00%Buy
MDGL$315.46$442.50+40.27%Strong Buy
NNNN$49.26N/AN/A
HALO$57.15$66.40+16.19%Buy
View Top Biotech Stocks

Jazz Pharmaceuticals Stock Forecast FAQ

Is Jazz Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NASDAQ: JAZZ) stock is to Strong Buy JAZZ stock.

Out of 12 analysts, 7 (58.33%) are recommending JAZZ as a Strong Buy, 4 (33.33%) are recommending JAZZ as a Buy, 1 (8.33%) are recommending JAZZ as a Hold, 0 (0%) are recommending JAZZ as a Sell, and 0 (0%) are recommending JAZZ as a Strong Sell.

If you're new to stock investing, here's how to buy Jazz Pharmaceuticals stock.

What is JAZZ's earnings growth forecast for 2025-2027?

(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual earnings growth rate of 48.52% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.69%, and it is also forecast to beat the US market's average forecast earnings growth rate of 15.82%.

Jazz Pharmaceuticals's earnings in 2025 is $482,197,000.On average, 9 Wall Street analysts forecast JAZZ's earnings for 2025 to be $127,099,245, with the lowest JAZZ earnings forecast at $28,351,107, and the highest JAZZ earnings forecast at $179,351,567. On average, 9 Wall Street analysts forecast JAZZ's earnings for 2026 to be $1,096,516,038, with the lowest JAZZ earnings forecast at $946,064,109, and the highest JAZZ earnings forecast at $1,332,502,022.

In 2027, JAZZ is forecast to generate $1,277,235,854 in earnings, with the lowest earnings forecast at $1,155,615,769 and the highest earnings forecast at $1,505,690,306.

What is JAZZ's revenue growth forecast for 2025-2027?

(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 5.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Jazz Pharmaceuticals's revenue in 2025 is $4,064,808,000.On average, 10 Wall Street analysts forecast JAZZ's revenue for 2025 to be $261,447,497,647, with the lowest JAZZ revenue forecast at $256,210,185,351, and the highest JAZZ revenue forecast at $268,780,819,601. On average, 10 Wall Street analysts forecast JAZZ's revenue for 2026 to be $277,387,044,620, with the lowest JAZZ revenue forecast at $261,975,382,931, and the highest JAZZ revenue forecast at $291,920,253,426.

In 2027, JAZZ is forecast to generate $297,425,606,948 in revenue, with the lowest revenue forecast at $278,198,317,706 and the highest revenue forecast at $315,714,228,023.

What is JAZZ's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: JAZZ) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 44.42%.

What is JAZZ's Price Target?

According to 12 Wall Street analysts that have issued a 1 year JAZZ price target, the average JAZZ price target is $183.08, with the highest JAZZ stock price forecast at $230.00 and the lowest JAZZ stock price forecast at $147.00.

On average, Wall Street analysts predict that Jazz Pharmaceuticals's share price could reach $183.08 by Jun 11, 2026. The average Jazz Pharmaceuticals stock price prediction forecasts a potential upside of 66.03% from the current JAZZ share price of $110.27.

What is JAZZ's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: JAZZ) Jazz Pharmaceuticals's current Earnings Per Share (EPS) is $7.79. On average, analysts forecast that JAZZ's EPS will be $2.06 for 2025, with the lowest EPS forecast at $0.46, and the highest EPS forecast at $2.91. On average, analysts forecast that JAZZ's EPS will be $17.79 for 2026, with the lowest EPS forecast at $15.35, and the highest EPS forecast at $21.62. In 2027, JAZZ's EPS is forecast to hit $20.72 (min: $18.75, max: $24.43).

What is JAZZ's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: JAZZ) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.